Belgian biotech BioSenic has suspended a phase 2b trial of ALLOB – a stem cell-derived therapy designed to accelerate bone fracture healing – after it was unable to show e
An artificial intelligence-based tool for identifying hard-to-detect spinal fractures, developed by Belgian drugmaker UCB, has been licensed out to ImageBiopsy Lab for further development.<
US biotech Inozyme Pharma is the latest to jump on to the IPO bandwagon, setting terms for a $75 million stock market launch, as the firm gears up for clinical trials of its lead drug for r
The US regulator has approved a new use for Amgen’s blockbuster bone drug Xgeva, to prevent fractures in patients with newly-diagnosed multiple myeloma with bone metastases.
The venture capital arms of MSD and Amgen have provided $10 million in funding to Culmination Bio, a Utah start-up that aims to build the largest disease-agnostic patient
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio